Organic Active Ingredients TRIZ Cases

A distinct PPARγ agonist binding mode cuts proteinuria and glomerular injury while avoiding the weight gain and edema seen with older agents.

A porous implant scaffold enables tissue ingrowth before insulin-expressing cell infusion, improving vascularization and reducing immune damage.

Copper-mediated hydrazone cyclization improves 2-aryl triazole selectivity, raising yield while cutting waste and separation cost.

Recombinant CD20-presenting antigen cells activate T cells to selectively kill B cell lymphoma cells where chemo and radiation lack targeting.

Adenosine deaminase base editing corrects ABCA4 pathogenic variants to restore gene function and help slow progressive vision loss.

A higher anti-CD19 antibody dose extends dosing intervals, reducing hospital visits and infection exposure while maintaining efficacy.

A Lewis acid and sulfuric acid-water sequence improves viloxazine intermediate purity while controlling exotherms for industrial synthesis.

Targeting NASP RNA splicing with splice-switching oligonucleotides reveals therapeutic vulnerability in high-risk meningioma cells.

Encapsulating self-amplifying IL-12 replicon RNA in lipid nanoparticles drives local immunogenic cell death and systemic tumor immunity.

Crystalline PC945 forms improve stability, micronization, and lung-site bioavailability for inhaled treatment of invasive fungal infections.

Binding two distinct FRα epitopes improves ADC delivery and tumor cell killing in high FRα-expressing cancers, including ovarian cancer.

A flexible six-month paliperidone palmitate regimen uses a defined dosing window and re-initiation steps to improve adherence and reduce relapse risk.

Using S-1-propenylcysteine to raise blood eNAMPT and NAD+ offers a route to sirtuin activation and senescent cell suppression.

A dual-pathway blend of resistant starch, amino acids, vitamins, and electrolytes speeds rehydration while extending hydration effect.

Novel benzisoxazole sulfonamide derivatives improve KAT inhibition and MYST family selectivity to help regulate abnormal cell growth.

Lipid-based pleconaril formulations improve sepsis treatment by boosting bioavailability and targeted delivery while limiting systemic side effects.

Twice-daily Compound 1 dosing sustains plasma levels and brain penetration needed to treat mIDH1 cancers such as glioma and AML.

Focused CBC derivative compounds expand therapeutic use across cancer, neurodegenerative, psychiatric, and pain indications with controlled dosing.

A layered nanoparticle uses pH-triggered release and magnetic targeting to improve bioavailability while limiting off-target senolytic toxicity.

Using kojibiose-based oligosaccharides, this case shows how to raise Parabacteroides and Bifidobacterium without direct probiotic delivery.

Selective topical mTOR inhibitors improve skin penetration and stability to treat skin disorders with lower systemic side effects.

Direct nasal delivery of apigenin with a linear peptide inhibitor targets mitochondrial dysfunction in neural cells to reduce oxidative stress and cell death.

Fatty acid precursors stimulate MSCs to produce pro-resolving mediators that reduce osteoarthritis inflammation and support joint tissue regeneration.

A tear-compatible JAK inhibitor eye drop improves ocular bioavailability and treats non-infectious uveitis with fewer side effects.

A circularizing domain masks oligonucleotide ends to improve nuclease stability, limit PRR-driven immune activation, and enable intracellular release.

Chelating green tea bioactives with iron creates a powdered extract that eases gastrointestinal symptoms while avoiding common side effects.

PP2A-modulating aminotetrahydropyran derivatives suppress MYC signaling and help restore chemotherapy sensitivity in resistant cancers.

Substituted heterocycles tune KRAS inhibition, solubility, and normal-cell cytotoxicity to support cancer treatment.

MAS receptor agonists stimulate mitophagy and mitochondrial turnover to address diseases linked to inadequate mitochondrial renewal.

Mild extracellular potassium elevation boosts flecainide action to improve AF conversion, shorten termination time, and lower proarrhythmia risk.

A selective FGFR3 inhibitor targets FGFR3-altered solid tumors to limit off-target toxicity and address resistance seen with pan-FGFR drugs.

A non-aqueous 1.8% lidocaine patch uses a composite adhesive matrix to limit crystallization, improve skin permeation, and sustain release.

Pyrrolopyridine JAK1/JAK3 inhibitors are tuned for topical or oral delivery to preserve efficacy while limiting systemic toxicities.

A closed automated CAR T workflow uses activating lentiviral vectors to raise transfection efficiency, reduce contamination risk, and support infusion.

Biased Kv7 activators raise Kv7.2/7.3 current while limiting Kv7.4 activity, helping reduce concentration-linked side effects.

Tocopherol-modified oligonucleotides form a dense anionic shell that keeps small liposomes stable and aggregation-resistant for gene delivery.

Biomarker profiling links multiple myeloma progression and chemoresistance risk to gene-expression targets, enabling more personalized treatment.

Cell-targeted oligonucleotide conjugates use nucleotide and linkage modifications to drive exon skipping or inclusion and restore functional proteins.

Blocking PD-1 restores T-cell activity to cut HBV particle load and improve symptoms when standard HBV treatments fail to clear infection.

Combining cellular kinase inhibitors with IAP-targeting formula I compounds improves proliferative disease treatment while maintaining non-toxic properties.

BDDE-crosslinked hyaluronic acid gel evenly disperses triamcinolone to improve stability and extend osteoarthritis relief.

Modified ABE8 with guide RNA targeting corrects HBB SNPs linked to sickle cell disease, achieving over 60-70% editing efficiency.

New MYST family KAT inhibitor compounds use scaffold and substituent tuning to improve selectivity while maintaining anticancer activity.

Targeted endothelin injury in primate basal ganglia and thalamus creates a reproducible chronic stroke model for evaluating NeuroD1 therapy.

Short-chain polyhomoarginine improves corneal penetration and bioavailability while rapidly inhibiting fungal and bacterial infections.

Vision sensors and AI quantify exposure, viewing, and attention around outdoor ads in real time, improving measurement accuracy for campaign optimization.

Glycosylated hydroxytryptamine compounds modulate serotonin receptors to deliver alcohol-like recreational effects without hangovers or liver damage.

A dual-matrix tablet uses hydrophilic and insoluble release agents to lower peak PDE10 plasma levels while sustaining therapeutic exposure.

A fixed-ratio combination with 5-amino-2,3-dihydro-1,4-phthalazinedione boosts anti-inflammatory efficacy while lowering fumaric ester dosage and side effects.

Combining chidamide, sintilimab, and IBI305 improves MSS/MSI-L colorectal cancer response rates while prolonging progression-free survival.

Novel piperidinedione CRBN binders improve PROTAC target protein degradation, supporting anticancer and immunomodulatory use.

A 1-cyano nucleoside scaffold is tuned with substituent changes to treat multiple viral families while maintaining therapeutic efficacy.

Specific amino acid ratios keep IL-6 within physiological levels to reduce skin inflammation while preserving immune response and collagen-elastin synthesis.

Selective TYK2 compounds treat autoimmune, inflammatory, and proliferative disorders while minimizing JAK2 off-target side effects.

Natural pectin from fruit pulp forms nano/microcapsules that stabilize bioactives, improve taste, and enable gradual digestive release.

Formula (I) pyrrolo and pyrazolopyrimidine compounds selectively inhibit USP7 to expand treatment options while improving efficacy and safety.

Chlorotoxin-based CAR γδT cells improve glioma selectivity while limiting off-target tissue effects and retaining activity during chemotherapy.

Modular TYK2 inhibitor scaffolds improve kinase selectivity, helping treat autoimmune and inflammatory disorders while sparing JAK2.

Macrocyclic FKBP51 binders use topology and substituent tuning to improve selectivity and affinity without excessive molecular weight or lipophilicity.

Engineered zinc finger transcription factors repress MAPT expression to lower tau levels and slow tau aggregation in Alzheimer's-related tauopathy.

A non-cleavable PEG lipid uses pH-triggered positive charge to form stable bioactive particles and improve target-cell delivery.

Heating and curing the fabric before adding the active-substance binder reduces volatilization and improves immediate flavor release.

A pH 3.0-3.6 epinephrine liquid formulation uses organic acid buffering to extend room-temperature shelf life while limiting impurities.

Engineered gut-colonizing microbes produce L-DOPA continuously, helping reduce dyskinesia risk while sustaining Parkinson's symptom relief.

Tocopheryl phosphates with long-chain lipids improve oral cannabinoid solubilization and absorption, raising bioavailability, cMax, and AUC.

A multi-solvent lipoxygenase inhibitor formulation enables 30 mg/mL or higher IV dosing while overcoming solubility limits.

mTOR and antiviral restriction factor inhibitors help pseudotyped viral vectors overcome cellular barriers and improve exogenous agent delivery.

A polymer-based amorphous solid dispersion improves solubility, limits food effect, and maintains oral exposure for BNC210 tablets.

Controlled extraction of fish-testes DNA tunes fragment size for oral use against osteoarthritis, bone resorption, and oxidative stress.

Heterobifunctional PROTAC compounds recruit E3 ligase to ubiquitinate and degrade BTK, enabling stronger control of BTK-driven cancers.

pH adjustment and disodium edetate keep injectable fosnetupitant soluble, stable, and less prone to degradation or injection site reactions.

Specific Formula (I) substituent patterns improve JAK1 selectivity while limiting other JAK kinase activity and related side effects.

Multiple dispense streams and controlled conditions prevent freezing and agglomeration during pharmaceutical cryogranulation, improving pellet yield.

Blocking oxidation of OTUB1 Cys23/Cys204 disrupts system xC-, depletes GSH, and sensitizes cancer cells to chemo and checkpoint therapy.

Amino lipid LNPs use pH-responsive self-assembly to improve nucleic acid encapsulation, endosome escape, and safety in delivery.

Aminoalkyl monomethyl fumarate prodrugs sustain therapeutic levels for 8-24 hours, improving bioavailability while reducing flushing and GI effects.

A small molecule activates JWA gene expression to delay aging, support homeostasis, and address aging-related disease treatment.

Heat-treated compressed matrices use swelling polymer and pH regulation to improve gastric retention and sustain near zero-order drug release.

Combining a formula I FAK inhibitor with doxorubicin improves antitumor response in platinum-resistant ovarian cancer while reducing toxicity.

Pharmaceutically usable naphthylamine salt forms improve selective mitophagy, crystalline stability, and bioavailability for mitochondrial dysfunction.

Solvent exchange in acidic aqueous solution creates stable imipridone dihydrochloride crystal forms with better filterability, purity, and handling.

pH-modifying excipients and penetration enhancers help sublingual epinephrine absorb rapidly and reliably despite saliva-driven instability.

Targeting PUM1 with vesicle-delivered antisense oligomers boosts interferon-stimulated genes and suppresses HSV-1 replication.

Low-cost phenazine derivatives enable fluorescent one- and two-photon cancer imaging and photodynamic cell killing with reduced tissue damage.

Splice-switching oligonucleotides target ATM NSE motifs to raise or lower functional ATM protein in ataxia-telangiectasia and cancer.

A citrate-sulfate lyophilizate stabilizes disodium 5,10-methylene-(6R)-tetrahydrofolate while preserving solubility and high active loading.

Small-molecule EAAT2 activators raise transporter expression to improve glutamate reuptake and reduce neuronal damage from excitotoxicity.

Adding 2'FL and LNnT to hypoallergenic infant formula helps limit premature gut microbiota maturation in infants with cow's milk protein allergy.

Cholesterol-free sphingomyelin nanoparticles use ionizable lipids to improve nucleic acid delivery while lowering immunogenicity and toxicity.

Gap junction modulators such as danegaptide help preserve the outer blood-retina barrier, reducing leakage and slowing AMD progression.

Combining liposomal irinotecan with 5-fluorouracil and leucovorin improves SN-38 tumor exposure to extend survival with lower toxicity.

Combining anti-CD38 antibodies with carfilzomib helps overcome myeloma treatment resistance through complementary tumor-killing mechanisms.

RNAi oligonucleotides inhibit GYS2 expression in hepatocytes to reduce hepatomegaly, liver toxicity, and related glycogen storage disease symptoms.

Using C18:1 monoglycerides in post-weaning pig diets improves feed intake, daily gain, and intestinal villi growth while reducing treatments.

Reduced elinzanetant dosing with moderate CYP3A4 inhibitors preserves relief of vasomotor symptoms and sleep disturbances while avoiding toxic plasma levels.

Encapsulated ASS1 mRNA restores urea cycle enzyme production, lowering plasma ammonia and citrulline in argininosuccinate synthetase deficiency.

Specific ionizable lipid LNP compositions improve capsid-free DNA delivery while lowering liver toxicity and supporting repeat dosing.

By inhibiting mitochondrial complex I, this disubstituted adamantyl derivative lowers ATP, degrades HIF-1α, and suppresses tumor growth.

PAAG polyglucosamine reduces mucus viscosity and biofilm cohesion to improve mucociliary clearance and support antibiotic treatment.

A self-emulsifying cannabinoid tablet boosts GI uptake at high load while avoiding sandy mouthfeel and improving pH stability.

Hydrolyzed alginic acid with molecular weight 10,000 or less helps Faecalibacterium prausnitzii grow and raise butyric acid production.

Genetically modified γδ T-cells resist chemotherapy toxicity, enabling concurrent chemo-immunotherapy with stronger tumor cell killing.

Defined oligosaccharides shift gut microbiota toward SCFA production, reducing inflammation and pathogenic bacteria in inflammatory bowel disease.

Combining naloxone with atipamezole broadens overdose treatment to xylazine-tainted opioids while addressing withdrawal and sedation.

Covalently crosslinked polysaccharide hydrogel capsules tune stability and deliver afibrotic protection to reduce foreign body response.

Specific promoter proximal nucleotide patterns raise RNA transcription yield while maintaining purity, helping lower therapeutic RNA manufacturing cost.

Compounds targeting the Syk lipid-binding site inhibit phosphorylation and cell proliferation while overcoming resistance to ATP-competitive inhibitors.

A dendrimer with radionuclide and pharmacokinetic terminal groups improves tumor accumulation, imaging sensitivity, and therapy from one scaffold.

Glutarimide-based isoindolinone derivatives tune CRBN binding to retain anticancer activity while reducing severe thalidomide side effects.

By driving cancer cells into a temporary dormant state, herring sperm DNA can slow replication and create a better window for chemotherapy.

A Ser25-nonphosphorylated FoxM1 mutant or FoxM1 shRNA suppresses tumor growth, invasion, metastasis, and macrophage polarization.

Chromene derivatives block TCR-Nck binding to modulate T-cell activation more specifically, helping treat autoimmune disease with fewer side effects.

A crystalline Form III BTK inhibitor with acidulants preserves exposure and efficacy when acid-reducing agents would otherwise lower bioavailability.

Small-molecule ROR modulators raise endogenous FGF21 for oral treatment of pancreatitis and other FGF21-deficient disorders.

Humanized anti-CD40 antibodies block CD40-CD40L signaling to suppress autoimmune responses and improve graft survival through immune tolerance.

A combined oleuropein and fisetin composition boosts mitochondrial calcium uptake and energy while reducing oxidative stress linked to metabolic fatigue.

Targeted substituent tuning on a pyrrolopyrimidinone scaffold improves BTK inhibition potency and specificity, including against mutant forms.

Ultra-high gaseous nitric oxide primes tumors for checkpoint inhibitors by boosting checkpoint protein expression and CD8+ immune responses.

Mitoxantrone derivatives disrupt RAS-effector interactions to inhibit KRAS, HRAS, and NRAS while helping address resistance to mutation-specific inhibitors.

Selective DYRK1A inhibition modulates T cell differentiation, lowers pro-inflammatory cytokines, and improves inflammatory skin disease models.

An ERAD-based chimeric protein redirects target proteins to proteasome and autophagy pathways for more specific degradation with fewer off-target effects.

Selective 5-HT2A/2C modulators retain neuroplastic therapeutic effects while avoiding hallucinations and cardiotoxicity for at-home dosing.

A segmented 28-day Minnelide-paclitaxel regimen improves gastric cancer tumor control while limiting dose-related toxicity and side effects.

Storage sensors and a logger let the inhaler adapt heating and airflow to keep botanical substance release predictable over time.

Dual tannic acid and Ca2+ cross-linking tightens zein-chitosan nanoparticles to protect quercetin during heating and improve retention.

PDE1 inhibitors raise cAMP to curb macrophage recruitment and metastasis while boosting checkpoint therapy and limiting inflammation.

Episodic dosing of a GABAA-modulating steroid treats depression with fewer administrations, lower side effects, and better compliance.

Micronization, ethylene oxide sterilization, and 30–40% humidity control improve artesunate flowability for accurate packaging.

Modified RNAi agents target hepatocytes and suppress C3 expression, addressing frequent dosing and limited durability in complement-mediated diseases.

Parenteral RALDH modRNA drives mucosal homing receptors and antigen-specific immunity while avoiding oral tolerance and ATRA toxicity.

Carbazole derivatives activate NAMPT to protect peripheral neurons during chemotherapy while preserving and enhancing anti-tumor activity.

Novel pyrazole fused ring FGFR inhibitors are tuned to keep FGFR3 activity high while addressing resistance and treatment-related adverse events.

Hot-melt extruded amorphous apixaban with polymers improves solubility, bioavailability, content uniformity, and shelf stability.

Targeted deaminase editing corrects LHON mitochondrial mutations at 3460, 11778, and 14484 to support disease treatment.

Transamination of keto and hydroxy analogues supplies amino acids while helping lower nitrogen content in restricted-protein diets.

Complex preparation and rapid degradation limit hydrogel drug delivery; PETO-ITA8 self-assembly supports immunomodulation and wound repair.

Osteoarthritis therapies often relieve pain without stopping cartilage destruction; substituted pyridoindoles target chondrogenesis and matrix synthesis.

Rapid release and limited payloads constrain nitric oxide therapies; hyperbranched scaffolds enable controlled release that damages bacterial membranes and DNA.

Procaine, peptide, DNase 1, and optional RNase A combine to disrupt viral entry while inhibiting adenocarcinoma growth.

Rapid absorption can produce minoxidil peaks linked to tachycardia and hypotension; modified release sustains therapeutic levels for hair-loss treatment.

Existing Hv1 inhibitors are ineffective, while marine fungi-derived S1 and S2 compounds block 85–92% of proton current.

CCCP, FCCP, and rotenone induce mitophagy but are too cytotoxic; isoquinoline derivatives offer a drug-compatible alternative.

Existing bradykinin inhibitors show limited efficacy and specificity; modified ethylenediamine derivatives target B1R/B2R for anti-tumor activity.

Small-molecule TREM2 modulators aim to restore blunted microglial responses linked to loss-of-function variants and neurodegeneration.

Form C changes capsaicin palmitate’s solid structure to preserve analgesic effect while reducing thermal irritation in topical treatment.

Selected crystalline form F supports moderate-condition synthesis with higher yield and purity while reducing extra purification steps.

Human milk oligosaccharides promote gut maturation and feeding tolerance while reducing NEC incidence in C-section-born infants.

With SSRIs taking weeks to act, PA-8 and PA-9 use PAC1 antagonism for fast, sustained anxiety and depression effects without sedation.

Cellulose and hydrocolloids create an oral pad that guides tongue posture and movement while dissolving for simple, hygienic training.

Intravenous dextroamphetamine provides rapid awakening while lisdexamfetamine sustains dexmedetomidine reversal and limits re-sedation risk.

Antisense oligonucleotides skip mutated exons in CFTR transcripts, restoring open reading frames and correcting premature termination codons.

Administering antioxidants to reduce oxidative stress in the joint microenvironment improves stem cell engraftment and cartilage regeneration.

Probiotic fermentation transforms complex ginsenosides into rare metabolites to boost bioavailability.

A cardiac sarcomere activator dosing regimen adjusts omecamtiv mecarbil levels based on plasma concentration measurements.

Segmented dose adjustment mechanisms control fluticasone and salmeterol levels to minimize cardiac side effects while maintaining lung function.

Allosteric binding of an oxygen-containing heterocyclic compound bypasses strong GTP affinity to inhibit Ras for treating mediated diseases.

Combining oleuropein aglycone with nicotinamide riboside boosts mitochondrial calcium uptake to enhance cellular energy production.

Administering a VLA-1 antagonist blocks pathological cell adhesion, reducing ischemic damage and improving clinical outcomes in stroke treatment.

Modified quinuclidine structure enhances anti-inflammatory action to treat chronic obstructive pulmonary disease.

Incorporating oncoselective translation motifs into mRNA constructs enables targeted therapeutic payload delivery while minimizing off-target toxicity.

Compounds up-regulate E-cadherin expression to stabilize the intestinal epithelial barrier and reduce permeability.

Computational network analysis identifies estradiol as a repurposed agent to inhibit cancer cell proliferation, reducing development time and cost.

Carbodiimide coupling agents crosslink hyaluronic acid at mild pH and temperature to prevent Tyndall effect blue discoloration in superficial injections.

Novel indazole-substituted diaminopyrimidines inhibit tubulin polymerization and induce apoptosis in cancer cells.

Amino-modified bile acid derivatives modulate FXR and TGR5 receptors, resolving selectivity trade-offs in metabolic disease treatment.

A hydrogel with unimolecular micelles delivers anti-stenotic drugs to the periadventitial surface of blood vessels.

Substituted pyrimidinone derivatives inhibit lysine specific demethylase-1 to treat acute myeloid leukemia and other cancers.

Estrone repurposing reduces development time and side effects by leveraging existing safety data to treat ovarian and breast cancers.

Succinyl ester modification of emodin improves oral bioavailability and reduces toxicity, addressing adverse reactions from statins.

Merges GABA(B)R and alpha-2 adrenergic agonists to address inadequate efficacy and slow onset in stress-induced depression.

Pyrimidine derivatives with tailored substituents inhibit ALK, FAK, ZAP-70, and IGF-1R to treat proliferative disorders.

A composition containing citric acid and its salts increases muscle mass in mammals.

Solution electrospun fibers achieve high drug loading up to 70% w/w by lowering polymer concentration below standard electrospinnability thresholds.

Combining CK2 and ATM kinase inhibitors achieves synthetic lethality in VHL null renal carcinoma cells, overcoming resistance to conventional therapies.

Detecting BMP6 overexpression and salivary gland electrical potential enables precise diagnosis of Sjögren's syndrome.

Thiophosphate DNA aptamers stabilize in vivo and inhibit AXL receptor kinase, reducing tumor growth and metastasis.

Gluconate and thioglycerol stabilize aqueous folate solutions, preventing precipitation and enabling high concentrations without cold chain storage.

Supercritical fluid injection forms nucleic acid-loaded nanosomes, achieving 40 to 100 percent siRNA encapsulation efficiency.

Pentagalloyl glucose treatment stabilizes collagen scaffolds against hyperglycemic stiffness and inflammation while preserving tissue remodeling capacity.

A lynx1-loop2-derived peptide conjugated to an effector agent moves therapeutic molecules across the blood-brain barrier.

Cationic mucic acid polymer nanoparticles extend siRNA circulation time by reducing excess cationic components that cause adverse reactions.

Isoquinolin and naphthyridin compounds inhibit Apoptosis Signal-Regulating Kinase 1 activity.

Compositions combining benzydamine with amino acids reduce mucositis severity and progression during cancer therapy.

Tasquinimod modifies Roquinimex structure to inhibit S100A9, reducing tumor burden and extending survival in acute leukemia models.

Characterizing ABT-888 Crystalline Form 2 via trigonal lattice parameters and diffraction patterns for stable pharmaceutical manufacturing.

LAG-3 protein activates antigen-presenting cells via MHC class II binding, improving progression-free survival in Luminal B breast cancer patients.

Specific TLR4 modulators resolve low efficacy and safety trade-offs by optimizing molecular parameters for precise inflammation reduction.

Non-steroidal pyrrolidin-2-one derivatives provide superior androgenic activity while eliminating liver burden associated with steroid-based therapies.

Blocking PD-1, PD-L1, or PD-L2 interactions restores anergic CD8+ T cell functionality to clear persistent infections and cancer.

Amino acid composition comprising leucine, arginine, glutamine, and N-acetylcysteine alleviates fatigue and improves mitochondrial function.

C17-substituted neuroactive steroids modulate GABA receptors, resolving inconsistent dose-response relationships in treating CNS disorders.

Combines an androgen receptor agonist with a bisphosphonate in biodegradable polymer depots to accelerate bone formation.

Gelled aqueous phases mask the unpleasant taste and smell of fish oils, improving swallowability for children and elderly patients.

Benzimidazole compounds target the STING cyclic dinucleotide binding pocket to achieve potent inhibition while reducing off-target effects.

A mucosal vaccine composition delivers WT1 peptides to induce cellular immunity without invasive injection procedures.

Self-assembled amphiphilic nanoparticles protect RNPs from degradation while enabling efficient cellular uptake.